[Radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab and anti-nucleus antigen monoclonal antibody chTNT in nude mice bearing human hepatocellular carcinoma].
OBJECTIVE
To evaluate the feasibility and efficacy of radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab (131 I-anti-HBsAg Fab) combined with 131 I-labeled anti-nucleus antigen monoclonal antibody chTNT (131 I-chTNT) in nude mice bearing human hepatocellular carcinoma.


METHODS
Nude mice bearing subcutaneous human hepatocellular carcinoma xenografts were treated by intratumoral injection of 131 I-anti-HBsAg Fab and/or 131 I-chTNT, and the changes in the tumor size and alterations in the radioactivity concentration in the tumor and non-tumor tissues were observed.


RESULTS
The tumor inhibition rate in mice treated with 131 I-anti-HBsAg Fab combined with 131 I-chTNT (73.09%) was significantly higher than that in mice treated with 131 I-anti-HBsAg Fab (47.8%) or 131 I-chTNT (54.26%) alone. Combined treatment also resulted in significantly higher tumor-to-normal radioactivity concentration ratios than the treatment with the single agents.


CONCLUSIONS
Intratumoral injection with 131 I-labeled monoclonal antibodies can increase the radioactivity concentration in the tumor and enhance the efficacy of the radioimmunotherapy in nude mice bearing human hepatocellular carcinoma.
DU
Yang-feng
YF
Oncology Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. dyfer11@126.com
Luo
Rong-cheng
RC
Li
Gui-ping
GP
Li
Ai-min
AM
Ding
Xue-mei
XM
Yan
Xiao
X
Huang
Kai
K
D000818:Animals; D000974:Antibodies, Antinuclear / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008114:Liver Neoplasms, Experimental / Q000473:pathology / Q000532:radiotherapy*; D051379:Mice; D008819:Mice, Nude; D016499:Radioimmunotherapy / Q000379:methods*; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D006514:Hepatitis B Surface Antigens; D018796:Immunoconjugates; D007140:Immunoglobulin Fab Fragments; D007457:Iodine Radioisotopes